Cleveland BioLabs, Inc. (NASDAQ: CBLI) is a biopharmaceutical company structured around development of novel approaches to activate the immune system and address serious medical needs. Having strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, Rusnano, and Everon Biosciences, the firm's proprietary platform of toll-like immune receptor activators (TLR) have relevant application in mitigation of radiation injury, radiation oncology, and immuno-oncology. Cleveland Biolab's product candidate is entolimod, an immune-stimulatory agent, used as a medical radiation countermeasure and other indications in radiation oncology. The firm is also working on a recombinant non-replicating adenovirus - designated Mobilan - that directs expression of TLR5 and its agonistic ligand; and on CBL0137, a small molecule with a multi-targeted mechanism for the treatment of various types of cancer.
